Atovaquone Nanosuspensions Show Excellent Therapeutic Effect in a New Murine Model of Reactivated Toxoplasmosis

Immunocompromised patients are at risk of developing toxoplasma encephalitis (TE). Standard therapy regimens (including sulfadiazine plus pyrimethamine) are hampered by severe side effects. While atovaquone has potent in vitro activity against Toxoplasma gondii, it is poorly absorbed after oral admi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Schöler, Nadja, Krause, Karsten, Kayser, Oliver, Müller, Rainer H., Borner, Klaus, Hahn, Helmut, Liesenfeld, Oliver
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Microbiology 2001
Aiheet:
Experimental Therapeutics
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC90544/
https://ncbi.nlm.nih.gov/pubmed/11353624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.45.6.1771-1779.2001
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia